期刊
CURRENT ALZHEIMER RESEARCH
卷 8, 期 5, 页码 592-606出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156720511796391935
关键词
Acetylcholine esterase inhibitors; adjunctive therapy; Alzheimer's disease; apolipoprotein E allele epsilon 4; cognition; phase 3; REFLECT; rosiglitazone
资金
- GlaxoSmithKline [NCT00348309, NCT00348140, NCT00490568]
- Bristol-Myers Squibb
- Pfizer Inc
- Abbott Laboratories
- Baxter Healthcare
- Medivation Inc
- Elan Pharmaceuticals
- Eli Lilly and Co
- Wyeth Pharmaceuticals
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety. Methods: In these two double-blind, placebo-controlled studies, subjects with mild-to-moderate probable AD were randomized within 2 apolipoprotein E (APOE) allelic strata (APOE epsilon 4-positive, APOE epsilon 4-negative) to once daily placebo, 2 mg RSG XR, or 8 mg RSG XR for 48 weeks (REFLECT-2, N=1,496; REFLECT-3, N=1,485). Co-primary efficacy endpoints were change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Clinical Dementia Rating scale - Sum of Boxes (CDR-SB) scores at week 48. Three populations were analyzed: APOE4-negative, all subjects except APOE epsilon 4 homozygotes, and the full intent-to-treat population. Results: No statistically or clinically relevant differences between treatment groups were observed on the a priori primary endpoints in REFLECT-2 or REFLECT-3. Edema was the most frequent adverse event with RSG in each study (14% and 19%, respectively, at 8 mg RSG XR). Conclusions: No evidence of statistically or clinically significant efficacy in cognition or global function was detected for 2 mg or 8 mg RSG XR as adjunctive therapy to ongoing AChEIs. There was no evidence of an interaction between treatment and APOE status. Safety and tolerability of RSG XR was consistent with the known profile of rosiglitazone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据